Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will report its first quarter financial results on May 3, 2023, before U.S. market opening. A conference call is scheduled for 8:30 a.m. ET the same day. Participants may pre-register for Q&A via telephone to receive dial-in details. The event will also be available as a live webcast. Pacira focuses on non-opioid pain management solutions and offers three commercial products: EXPAREL®, ZILRETTA®, and ioveraº®. These innovative interventions aim to reduce dependence on opioids and address various pain-related conditions.
Pacira BioSciences, Inc. has partnered with the Invited Celebrity Classic, a PGA TOUR Champions event, to promote non-opioid pain management using its device, iovera°. The device applies targeted cold therapy to alleviate chronic and acute pain without medications. Paul Goydos, a professional golfer, joins as a brand ambassador to raise awareness of iovera°.
The partnership includes on-site activations and education at various golf tournaments throughout the year, with the inaugural event occurring from April 21-23, 2023, at the Las Colinas Country Club. This initiative aims to highlight the benefits of non-opioid options and reduce reliance on opioid medications, which carry substantial addiction risks. Pacira currently focuses on redefining pain management through innovation.
Pacira BioSciences, Inc. (NASDAQ: PCRX) announced the appointment of Christopher Young as Chief Manufacturing Officer on April 19, 2023. Young, a seasoned operations executive, will oversee all manufacturing activities for Pacira's product portfolio, focusing on supply chain design, product life cycle management, and global product launches. Prior to joining Pacira, he held senior roles at Akorn Inc. and Alvogen Inc., demonstrating a strong track record in operational leadership and efficiency improvements. CEO Dave Stack praised Young for his team-building skills and operational expertise. Young expressed enthusiasm for contributing to Pacira's vision of providing opioid alternatives and enhancing patient care.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 10:15 AM ET. This event aims to provide insights into the company’s commitment to developing non-opioid treatments and innovative solutions for conditions affecting the sympathetic nervous system. Those interested can access the live audio on the company’s website, with a replay available for two weeks post-event.
Pacira focuses on redefining opioid use as a last resort by offering alternatives like EXPAREL, ZILRETTA, and iovera, aimed at managing pain and improving patient outcomes. For more information, visit their official site.
Pacira BioSciences (Nasdaq: PCRX) announced significant financial maneuvers, including the repayment of $287.5 million in Term Loan B debt on March 31, 2023. This was accomplished through a new $150 million Term Loan A Facility and existing cash. The company expects to have around $180 million in cash and investments by the end of Q1 2023. With the lower interest rate of the new loan—400 basis points lower than the previous facility—Pacira anticipates a reduction of at least $15 million in interest expenses for 2023. This move is projected to improve the company's debt leverage ratio and reaffirm their growth outlook.